20
Participants
Start Date
February 22, 2024
Primary Completion Date
September 11, 2026
Study Completion Date
September 11, 2026
NS-089/NCNP-02
"Cohort 1:~Part 1 Dose Level 1-3: a 4-week Treatment Phase at each treatment dose level~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1~Cohort 2:~Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1"
RECRUITING
University of Pittsburgh School of Medicine, Pittsburgh
RECRUITING
Virginia Commonwealth University Health System, Richmond
RECRUITING
Rare Disease Research, Atlanta
RECRUITING
Rare Disease Research, LLC - FL, Kissimmee
RECRUITING
Cincinnati Children's Hospital Medical Center, Cincinnati
RECRUITING
Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago
RECRUITING
University of Kansas Medical Center (KUMC), Kansas City
RECRUITING
UT Southwestern/Children's Health, Dallas
RECRUITING
Children's Hospital Colorado, Aurora
NOT_YET_RECRUITING
Alberta Children's Hospital, Calgary
RECRUITING
London Health Sciences Centre, London
NOT_YET_RECRUITING
Pusan National University Yangsan Hospital, Yangsan
NOT_YET_RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
National Hospital Organization Nagara Medical Center, Nagara
NOT_YET_RECRUITING
NHO Osaka Toneyama Medical Center, Toyonaka
NOT_YET_RECRUITING
Shiga General Hospital, Moriyama-shi
NOT_YET_RECRUITING
National Center of Neurology and Psychiatry, Kodaira
Lead Sponsor
Collaborators (1)
Nippon Shinyaku Co., Ltd.
INDUSTRY
NS Pharma, Inc.
INDUSTRY